SIM
ATXS

Spark Investment Management’s Astria Therapeutics ATXS Stock Holding History

Spark Investment Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,213
Closed -$69K – 667
2018
Q2 		$69K Buy
+1,213
New +$112K ﹤0.01% 620
2016
Q2 		– Sell
-203
Closed -$61K – 781
2016
Q1 		$61K Sell
203
-182
-47% -$62.7K 0.01% 735
2015
Q4 		$183K Sell
385
-157
-29% -$75.3K 0.02% 594
2015
Q3 		$263K Buy
+542
New +$387K 0.03% 491

Other funds holding ATXS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
OC
Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Spark Investment Management's ATXS Position: Q3 2018 in Review

Spark Investment Management sold out of Astria Therapeutics (ATXS) in Q3 2018, closing a stake of 1,213 shares — an estimated $69K sold.

Spark Investment Management first reported a position in ATXS in Q3 2015 and held it in 4 quarters. The position peaked at $263K in Q3 2015. 28 funds tracked by Wall St. Rank hold ATXS as of Q3 2018.

  • Spark Investment Management reported no remaining Astria Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Spark Investment Management sold 1,213 Astria Therapeutics shares in Q3 2018, an estimated $69K.
  • Spark Investment Management first reported a position in Astria Therapeutics in Q3 2015 and held it in 4 quarters.
  • Spark Investment Management's Astria Therapeutics position peaked at $263K in Q3 2015.
  • 28 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2018.

Based on Spark Investment Management's 13F filing for Q3 2018, filed 13 Nov 2018.